Biotechnology

Design Therapeutics

Design Therapeutics released FY2026 Q1 earnings on April 28 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.29 (forecast USD -0.336)

Design Therapeutics released FY2025 earnings on March 9 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2173 (forecast USD -1.315)

Design Therapeutics released FY2025 Q4 earnings on March 9, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2723 (forecast USD -0.3675)

Design Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3 (forecast USD -0.34)

Design Therapeutics released FY2025 9 Months earnings on November 5 (EST), actual revenue USD 0, actual EPS USD -0.9461

Design Therapeutics released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3356 (forecast USD -0.32)

Design Therapeutics released FY2025 Semi-Annual Earnings on August 7 (EST) with actual revenue of USD 0 and EPS of USD -0.6477

Design Therapeutics Annual Shareholders Meeting Elects New Directors

Design Therapeutics Begins DT-216P2 Clinical Trials for Friedreich's Ataxia Patients

Design Therapeutics released FY2025 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3121 (forecast USD -0.28)

Design Therapeutics reports major project progress, strong economic growth

Design Therapeutics Inc. Reports Q1 Net Loss of $17.7 Million

Design Therapeutics Inc reports Q4 loss of 28 cents per share

Design Therapeutics Reports Positive Phase 1 Trial Results for DT-168

Design Therapeutics to Present DT-168 Data at 2025 Eyecelerator

Design Therapeutics released FY2024 Annual Earnings on March 10 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.8763 USD (forecast -0.91 USD)

Design Therapeutics released FY2024 Q4 earnings on March 10 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2408 USD (forecast -0.275 USD)

Design Therapeutics released FY2024 9 Months Earnings on November 7, 2024 (EST), with actual revenue of 0 and EPS of -0.6353

Design Therapeutics released FY2024 Q3 earnings on November 7 (EST), actual EPS -0.2302 (forecast -0.26)

Meiwu Tech

Amesite

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

Phoenix Asia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Gen Digital - Rights

DSGN

Design Therapeutics pre-market down 5.79%; Amesite pre-market up 191.31%; InMed Pharmaceuticals pre-market up 168.84%; Rubico pre-market up 152.58%

Price Alert

Rubico

Pre-market hot trades in US stocks: Clinical data causes fluctuations, Design Therapeutics pre-market down 5.79%, where is market sentiment heading?

Design Therapeutics fell 3.46% in the after-hours market; BeiGene rose 1.22% in the after-hours market, with a transaction volume of USD 173,900; Natera rose 0.34% in the after-hours market, with a transaction volume of USD 98,500; Intellia Therapeutics rose 0.63% in the after-hours market, with a transaction volume of USD 98,400

Beigene

Natera

Intellia Therap

U.S. stock night trading volatility: Design Therapeutics fell 3.46% in after-hours trading, as positive news failed to counteract market sentiment fluctuations

FCEL

AEHR

LWLG

AXTI

BRUN

USAR

SGML

OUST

Design Therapeutics(DSGN) fell 25.54%, with a trading turnover 90.0 Million USD, and a year-to-date rose 14.1%. Rackspace Tech(RXT) fell 17.53%, with a trading turnover 149.9 Million USD, and a year-to-date rose 394.4%. FuelCell Energy(FCEL) fell 16.95%, with a trading turnover 280.1 Million USD, and a year-to-date rose 142.7%.

Top Gainers&Losers

Rackspace Tech

FuelCell Energy

Aehr Test

Lightwave Logic

Boost Run

USA Rare Earth

Sigma Lithium

Ouster

Top 10 US Stock Losers (5.18)

SBIO

ARKG

LABU

Design Therapeutics, Inc. stock's 12-month price target has been raised to $20, indicating a 39% upside from the previous average of $19.33. Analysts' forecasts range from $15 to $22 per share. The consensus rating remains a 'Buy' with 7 analysts recommending buys and none holding or selling.

TradingView

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

Factset Research

Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside

Shares of Design Therapeutics experienced a significant surge on Monday following positive results in the treatment of Friedreich's ataxia, reaching an increase of up to 18%. However, the biotech company quickly saw these gains disappear. This fluctuation underscores the volatile nature of the market, illustrating the rapid shifts that can occur in stock value. Investors Business Daily covered this story, highlighting the rollercoaster ride that Design Therapeutics' shares took on this particular day.

Unusual Whales

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Design Therapeutics(DSGN.US)

Pre-market hot trades in US stocks: Clinical data causes fluctuations, Design Therapeutics pre-market down 5.79%, where is market sentiment heading?

U.S. stock night trading volatility: Design Therapeutics fell 3.46% in after-hours trading, as positive news failed to counteract market sentiment fluctuations

Top 10 US Stock Losers (5.18)

Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All